Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERCY QUATTRO: Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis

NCT00291369 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT00291369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00291369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERCY QUATTRO: Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis
Lead sponsor
Centre Leon Berard
Phase
Phase 3
Overall status
Completed
Start date
December 31, 1999
Completion date
February 28, 2005
Enrollment
456
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma